A. Aszalós

1.2k total citations
57 papers, 1.0k citations indexed

About

A. Aszalós is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, A. Aszalós has authored 57 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 15 papers in Oncology and 13 papers in Organic Chemistry. Recurrent topics in A. Aszalós's work include Analytical Chemistry and Chromatography (7 papers), Drug Transport and Resistance Mechanisms (7 papers) and Immune Cell Function and Interaction (7 papers). A. Aszalós is often cited by papers focused on Analytical Chemistry and Chromatography (7 papers), Drug Transport and Resistance Mechanisms (7 papers) and Immune Cell Function and Interaction (7 papers). A. Aszalós collaborates with scholars based in United States, Hungary and Germany. A. Aszalós's co-authors include Ad Bax, Zoltán Dinya, P. Scott Pine, D D Ross, Sándor Damjanovich, James L. Weaver, Janet Crawford, Patricia E. Rao, Michael M. Gottesman and George C. Yang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and The Journal of Cell Biology.

In The Last Decade

A. Aszalós

57 papers receiving 968 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Aszalós United States 19 480 225 164 158 128 57 1.0k
Neal S. Burres United States 19 788 1.6× 159 0.7× 249 1.5× 445 2.8× 89 0.7× 30 1.5k
J. Mack United States 19 1.1k 2.3× 118 0.5× 82 0.5× 130 0.8× 88 0.7× 23 1.4k
N.R. Silvaggi United States 20 557 1.2× 195 0.9× 104 0.6× 153 1.0× 53 0.4× 37 1.2k
Jean Marie Ruysschaert Belgium 27 1.6k 3.3× 308 1.4× 69 0.4× 132 0.8× 170 1.3× 90 2.5k
Hans‐Rudolf Loosli Japan 21 1.1k 2.4× 279 1.2× 301 1.8× 530 3.4× 76 0.6× 46 2.2k
J.M. Ruysschaert Belgium 21 1.1k 2.2× 143 0.6× 31 0.2× 113 0.7× 98 0.8× 57 1.6k
François Leteurtre France 21 1.1k 2.3× 355 1.6× 118 0.7× 314 2.0× 70 0.5× 32 1.7k
T. L. NAGABHUSHAN United States 19 635 1.3× 151 0.7× 149 0.9× 489 3.1× 232 1.8× 33 1.2k
René Traber Switzerland 24 1.2k 2.4× 317 1.4× 329 2.0× 215 1.4× 138 1.1× 38 1.7k
Hideaki Tokuda Japan 9 688 1.4× 196 0.9× 101 0.6× 137 0.9× 93 0.7× 10 1.2k

Countries citing papers authored by A. Aszalós

Since Specialization
Citations

This map shows the geographic impact of A. Aszalós's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Aszalós with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Aszalós more than expected).

Fields of papers citing papers by A. Aszalós

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Aszalós. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Aszalós. The network helps show where A. Aszalós may publish in the future.

Co-authorship network of co-authors of A. Aszalós

This figure shows the co-authorship network connecting the top 25 collaborators of A. Aszalós. A scholar is included among the top collaborators of A. Aszalós based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Aszalós. A. Aszalós is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Aszalós, A., et al.. (2006). Multidrug Transporters as Drug Targets. Current Drug Targets. 7(8). 911–921. 47 indexed citations
2.
Balint, Elisabeth Maria, et al.. (2005). Plasma Membrane Biophysical Properties Linked to the Antiproliferative Effect of Interferon-a. Acta Microbiologica et Immunologica Hungarica. 52(3-4). 407–432. 5 indexed citations
3.
Aszalós, A.. (2003). Phenothiazines in treatment of HIV infection (A review). Acta Microbiologica et Immunologica Hungarica. 50(1). 43–53. 8 indexed citations
4.
Ibrahim, Sally, James O. Peggins, Alan Knapton, Thomas Licht, & A. Aszalós. (2000). Influence of Antipsychotic, Antiemetic, and Ca2+Channel Blocker Drugs on the Cellular Accumulation of the Anticancer Drug Daunorubicin: P-glycoprotein Modulation. Journal of Pharmacology and Experimental Therapeutics. 295(3). 1276–1283. 26 indexed citations
5.
Aszalós, A., et al.. (1999). Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp).. PubMed. 19(2A). 1053–64. 46 indexed citations
6.
Aszalós, A. & D D Ross. (1998). Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs.. PubMed. 18(4C). 2937–44. 45 indexed citations
7.
Szabó, Gábor, James L. Weaver, P. Scott Pine, Patricia E. Rao, & A. Aszalós. (1995). Cross-linking of CD4 in a TCR/CD3-juxtaposed inhibitory state: a pFRET study. Biophysical Journal. 68(3). 1170–1176. 12 indexed citations
8.
Balint, Elisabeth Maria, et al.. (1992). Modulation of the anti-proliferative signal of interferon-α by tamoxifen in U937 cells. Cancer Letters. 67(1). 13–19. 2 indexed citations
9.
Szabó, Gábor, P. Scott Pine, James L. Weaver, Patricia E. Rao, & A. Aszalós. (1992). CD4 changes conformation upon ligand binding. The Journal of Immunology. 149(11). 3596–3604. 22 indexed citations
10.
Pine, P. Scott, et al.. (1992). Epitope mapping by photobleaching fluorescence resonance energy transfer measurements using a laser scanning microscope system. Biophysical Journal. 61(3). 661–670. 52 indexed citations
11.
Weaver, James L., P Gergely, P. Scott Pine, Eric J. Patzer, & A. Aszalós. (1990). Polyionic Compounds Selectively Alter Availability of CD4 Receptors for HIV Coat Protein rgp120. AIDS Research and Human Retroviruses. 6(9). 1125–1130. 31 indexed citations
12.
Aszalós, A., et al.. (1989). Lymphocyte subpopulation with low membrane potential in the blood of cyclosporin- and prednisone-treated patients: In vivo selectivity for T4 subset. Biochemical Medicine and Metabolic Biology. 41(1). 25–29. 5 indexed citations
13.
Trón, Lajos, A. Aszalós, Margit Balázs, et al.. (1988). On the biophysics of transmembrane signalling. Molecular Immunology. 25(11). 1075–1080. 7 indexed citations
14.
Balint, Elisabeth Maria, et al.. (1988). Dynamic analyses of lymphoblast membranes exposed to alpha interferon using flow cytometry and fluorescence recovery after photobleaching.. PubMed. 2(4). 2153–63. 7 indexed citations
15.
Bax, Ad, R. Andrew Byrd, & A. Aszalós. (1984). Spin multiplet enhancement in two-dimensional correlated NMR spectroscopy. Journal of the American Chemical Society. 106(24). 7632–7633. 20 indexed citations
16.
Aszalós, A., et al.. (1980). Macrophage Cytostasis and T and B Cell Blastogenic Transformation in Mice Treated with Nystatin. PubMed. 2(3). 367–380. 3 indexed citations
17.
Aszalós, A., et al.. (1977). A carbon-13 nuclear magnetic resonance study of N-acetyldaunorubicinol. The Journal of Organic Chemistry. 42(13). 2344–2345. 3 indexed citations
18.
Issaq, Haleem J., et al.. (1977). Thin-layer chromatographic classification of antibiotics exhibiting antitumor properties. Journal of Chromatography A. 133(2). 291–301. 18 indexed citations
19.
Aszalós, A., N R Bachur, Bruce K. Hamilton, et al.. (1977). Microbial reduction of the side-chain carbonyl of daunorubicin and N-acetyldaunorubicin.. The Journal of Antibiotics. 30(1). 50–58. 21 indexed citations
20.
Roller, Peter P., Mary S. Sutphin, & A. Aszalós. (1976). Mass spectrometry ofN-acylated daunorubicin derivatives. Journal of Mass Spectrometry. 3(4). 166–171. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Neal S. Burres Breakdown of academic impact, for papers by J. Mack Breakdown of academic impact, for papers by N.R. Silvaggi Breakdown of academic impact, for papers by Jean Marie Ruysschaert Breakdown of academic impact, for papers by Hans‐Rudolf Loosli Breakdown of academic impact, for papers by J.M. Ruysschaert Breakdown of academic impact, for papers by François Leteurtre Breakdown of academic impact, for papers by T. L. NAGABHUSHAN Breakdown of academic impact, for papers by René Traber Breakdown of academic impact, for papers by Hideaki Tokuda
Rankless by CCL
2026